Using Ballistocardiogram and Impedance Plethysmogram for Minimal Contact Measurement of Blood Pressure Based on a Body Weight-Fat Scale

Monitoring microvascular changes over time with a repositionable 3D ultrasonic capacitive micromachined row-column sensor

eHealth devices, including smartwatches and smart scales, have the potential to transform health care by enabling continuous, real-time monitoring of vital signs over extended periods. Existing technologies, however, lack comprehensive monitoring of the microvascular network, which is linked to conditions such as diabetes, hypertension, and small vessel diseases. This study introduces an ultrasound approach using a capacitive micromachined ultrasound transducer row-column array for continuous, ultrasensitive three-dimensional (3D) Doppler imaging of microvascular changes such as hemodynamic variations or vascular remodeling. In vitro tests and in vivo studies with healthy volunteers demonstrated the sensor's ability to image the 3D microvascular network at high resolution over different timescales with automatic registration and to detect microvascular changes with high sensitivity. Integrating this technology into wearable devices could, one day, enhance understanding, monitoring, and possibly early detection of microvascular-related health conditions.

Using a Bodily Weight-Fat Scale for Cuffless Blood Pressure Measurement Based on the Edge Computing System

Blood pressure (BP) measurement is a major physiological information for people with cardiovascular diseases, such as hypertension, heart failure, and atherosclerosis. Moreover, elders and patients with kidney disease and diabetes mellitus also are suggested to measure their BP every day. The cuffless BP measurement has been developed in the past 10 years, which is comfortable to users. Now, ballistocardiogram (BCG) and impedance plethysmogram (IPG) could be used to perform the cuffless BP measurement. Thus, the aim of this study is to realize edge computing for the BP measurement in real time, which includes measurements of BCG and IPG signals, digital signal process, feature extraction, and BP estimation by machine learning algorithm. This system measured BCG and IPG signals from a bodily weight-fat scale with the self-made circuits. The signals were filtered to reduce the noise and segmented by 2 s. Then, we proposed a flowchart to extract the parameter, pulse transit time (PTT), within each segment. The feature included two calibration-based parameters and one calibration-free parameter was used to estimate BP with XGBoost. In order to realize the system in STM32F756ZG NUCLEO development board, we limited the hyperparameters of XGBoost model, including maximum depth (max_depth) and tree number (n_estimators). Results show that the error of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in server-based computing are 2.64 ± 9.71 mmHg and 1.52 ± 6.32 mmHg, and in edge computing are 2.2 ± 10.9 mmHg and 1.87 ± 6.79 mmHg. This proposed method significantly enhances the feasibility of bodily weight-fat scale in the BP measurement for effective utilization in mobile health applications.

Cuffless Blood Pressure in clinical practice: challenges, opportunities and current limits

Background: Cuffless blood pressure measurement technologies have attracted significant attention for their potential to transform cardiovascular monitoring.Methods: This updated narrative review thoroughly examines the challenges, opportunities, and limitations associated with the implementation of cuffless blood pressure monitoring systems.Results: Diverse technologies, including photoplethysmography, tonometry, and ECG analysis, enable cuffless blood pressure measurement and are integrated into devices like smartphones and smartwatches. Signal processing emerges as a critical aspect, dictating the accuracy and reliability of readings. Despite its potential, the integration of cuffless technologies into clinical practice faces obstacles, including the need to address concerns related to accuracy, calibration, and standardization across diverse devices and patient populations. The development of robust algorithms to mitigate artifacts and environmental disturbances is essential for extracting clear physiological signals. Based on extensive research, this review emphasizes the necessity for standardized protocols, validation studies, and regulatory frameworks to ensure the reliability and safety of cuffless blood pressure monitoring devices and their implementation in mainstream medical practice. Interdisciplinary collaborations between engineers, clinicians, and regulatory bodies are crucial to address technical, clinical, and regulatory complexities during implementation. In conclusion, while cuffless blood pressure monitoring holds immense potential to transform cardiovascular care. The resolution of existing challenges and the establishment of rigorous standards are imperative for its seamless incorporation into routine clinical practice.Conclusion: The emergence of these new technologies shifts the paradigm of cardiovascular health management, presenting a new possibility for non-invasive continuous and dynamic monitoring. The concept of cuffless blood pressure measurement is viable and more finely tuned devices are expected to enter the market, which could redefine our understanding of blood pressure and hypertension.

Non-invasive heart failure monitoring: leveraging smart scales and digital biomarkers to improve heart failure outcomes

Heart failure (HF) is a significant global concern, impacting patient morbidity, mortality, and healthcare costs. Guideline-directed medical therapy and various preventive measures have proven effective in improving clinical outcomes and reducing HF hospitalizations. Recent data indicates that remote HF monitoring facilitates early detection of HF decompensation by observing upstream events and parameters before clinical signs and symptoms manifest. Moreover, these innovative devices have been shown to decrease unnecessary HF hospitalizations and, in some cases, provide predictive insights before an actual HF incident. In this review, we aim to explore the data regarding smart scales and digital biomarkers and summarize both FDA-approved devices and emerging technologies by assessing their clinical utility, mechanism of HF decompensation detection, and ongoing trials. Furthermore, we also discuss the future trend of integrating these devices into routine clinical practice to improve patient clinical outcomes.